STOCK TITAN

vTv Therapeutics: Samsara sells 61,287 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

At vTv Therapeutics Inc. (VTVT), reporting person Samsara BioCapital, L.P. sold 61,287 shares of Class A common stock at $17.60 per share in a block trade on November 12, 2026. The shares were held for the exclusive benefit of limited partners who had redeemed their interests in Samsara LP; Samsara BioCapital GP, LLC and Srinivas Akkaraju had no economic interest in them.

Srinivas Akkaraju reported beneficial ownership of 412,654 shares, or 9.9%, with the percentage rounded down. The calculation used 4,011,465 shares outstanding as of November 5, 2026, and gave effect to warrants and options exercisable within 60 days, including 6,399 stock options. Warrant exercises are subject to a 9.99% beneficial ownership blocker.

Shares sold 61,287 shares Samsara BioCapital, L.P. block trade on November 12, 2026
Sale price $17.60 per share Samsara BioCapital, L.P. block trade on November 12, 2026
Srinivas Akkaraju beneficial ownership 412,654 shares Reported beneficial ownership, including securities exercisable within 60 days
Reported ownership percentage 9.9% Rounded down; based on 4,011,465 Class A shares outstanding as of November 5, 2026, with applicable warrants and options exercisable within 60 days included
Class A shares outstanding 4,011,465 shares As of November 5, 2026; used in the reported ownership-percentage calculation
Beneficial ownership blocker 9.99% Warrant exercise limit for each fund together with affiliates and other attribution parties
Stock options 6,399 options Held by Srinivas Akkaraju; vested or scheduled to vest within 60 days of the statement
Pre-Funded Warrants financial
"Pre-Funded Warrants exercisable for up to 1,447,400 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Common Warrants financial
"Common Warrants exercisable for up to 638,313 shares"
A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.
Beneficial Ownership Blockers financial
"provision (the “Beneficial Ownership Blockers”)"
block trade financial
"sold 61,287 shares of Class A common stock in a block trade"
A block trade is a large, privately arranged sale or purchase of a company's shares or bonds between big investors, often negotiated to avoid upsetting the public market price. Think of it like selling a truckload of goods directly to one buyer instead of unloading it on a busy street — it moves a lot of supply at once and can signal shifting demand, affect immediate liquidity, and influence short-term stock prices.
beneficially owned financial
"aggregate amount beneficially owned by each reporting person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many VTVT shares did Samsara BioCapital, L.P. sell, and at what price?

Samsara BioCapital, L.P. sold 61,287 shares at $17.60 per share on November 12, 2026, in a block trade. The shares were held for limited partners who had redeemed their interests in Samsara LP.

What percentage of VTVT did Srinivas Akkaraju report beneficially owning?

Srinivas Akkaraju reported beneficial ownership of 412,654 shares, or 9.9%, with the percentage rounded down. The calculation was based on 4,011,465 shares outstanding as of November 5, 2026, and gave effect to warrants and options exercisable within 60 days.

What limits exercise of Samsara's VTVT warrants?

The warrants contain a 9.99% beneficial ownership blocker, which bars exercise to the extent that exercise would cause Samsara LP or Samsara Opportunity Fund, together with affiliates and other attribution parties, to exceed that ownership level. The reporting persons also state that each fund is currently prohibited from exercising warrants if it would result in their beneficial ownership exceeding 412,654 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





918385204

(CUSIP Number)
Srinivas Akkaraju
Samsara BioCapital GP, LLC, 628 Middlefield Road
Palo Alto, CA, 94301
(650) 285-4270

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
11/12/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Samsara BioCapital, L.P.
Signature:/s/ Srinivas Akkaraju
Name/Title:By Samsara BioCapital GP, LLC, its General Partner, By Srinivas Akkaraju, Managing Member
Date:11/16/2026
Samsara BioCapital GP, LLC
Signature:/s/ Srinivas Akkaraju
Name/Title:By Srinivas Akkaraju, Managing Member
Date:11/16/2026
Samsara Opportunity Fund, L.P.
Signature:/s/ Srinivas Akkaraju
Name/Title:By Samsara Opportunity Fund GP, LLC, its General Partner, By Srinivas Akkaraju, Managing Member
Date:11/16/2026
Samsara Opportunity Fund GP, LLC
Signature:/s/ Srinivas Akkaraju
Name/Title:By Srinivas Akkaraju, Managing Member
Date:11/16/2026
Srinivas Akkaraju
Signature:/s/ Srinivas Akkaraju
Name/Title:Srinivas Akkaraju
Date:11/16/2026

Keep reading